Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics
Authors
Keywords
-
Journal
Frontiers in Neurology
Volume 6, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2015-08-31
DOI
10.3389/fneur.2015.00186
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Salivary Tau Species are Potential Biomarkers of Alzheimer's Disease
- (2018) Min Shi et al. JOURNAL OF ALZHEIMERS DISEASE
- Amyloid-β Oligomers in Cerebrospinal Fluid are Associated with Cognitive Decline in Patients with Alzheimer's Disease
- (2018) Alexander Navarrete Santos et al. JOURNAL OF ALZHEIMERS DISEASE
- BACE1 Activity in Cerebrospinal Fluid and Its Relation to Markers of AD Pathology
- (2017) Sandra D. Mulder et al. JOURNAL OF ALZHEIMERS DISEASE
- Serum Tau Fragments Predict Return to Play in Concussed Professional Ice Hockey Players
- (2016) Pashtun Shahim et al. JOURNAL OF NEUROTRAUMA
- Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease
- (2015) Hlin Kvartsberg et al. Alzheimers & Dementia
- Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research
- (2015) Sid E. O'Bryant et al. Alzheimers & Dementia
- Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease
- (2015) Kaj Blennow et al. Alzheimers & Dementia
- What does it mean to be ‘amyloid-positive’?
- (2015) Anne M. Fagan BRAIN
- Neuroinflammation in Alzheimer's disease
- (2015) Michael T Heneka et al. LANCET NEUROLOGY
- Invited review: Prion-like transmission and spreading of tau pathology
- (2015) Florence Clavaguera et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease
- (2015) Martin R Farlow et al. Alzheimers Research & Therapy
- Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age
- (2015) Courtney L. Sutphen et al. JAMA Neurology
- Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies
- (2015) Ju-Hee Kang et al. KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY
- A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease
- (2014) Eric Karran et al. ANNALS OF NEUROLOGY
- A data-driven model of biomarker changes in sporadic Alzheimer's disease
- (2014) Alexandra L. Young et al. BRAIN
- Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease
- (2014) Niklas Mattsson et al. BRAIN
- Oligomer Formation of Tau Protein Hyperphosphorylated in Cells
- (2014) Katharina Tepper et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
- (2014) Bruno Dubois et al. LANCET NEUROLOGY
- Soluble Aβ Oligomers Are Rapidly Sequestered from Brain ISF In Vivo and Bind GM1 Ganglioside on Cellular Membranes
- (2014) Soyon Hong et al. NEURON
- Antiamyloid Therapy for Alzheimer's Disease — Are We on the Right Road?
- (2014) Eric Karran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
- (2014) Stephen Salloway et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
- (2014) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Isoprostanes and Neuroprostanes as Biomarkers of Oxidative Stress in Neurodegenerative Diseases
- (2014) Elżbieta Miller et al. Oxidative Medicine and Cellular Longevity
- Ectosomes: A New Mechanism for Non-Exosomal Secretion of Tau Protein
- (2014) Simon Dujardin et al. PLoS One
- Distinct synthetic A prion strains producing different amyloid deposits in bigenic mice
- (2014) J. Stohr et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Neuronal failure in Alzheimer’s disease: a view through the oxidative stress looking-glass
- (2014) David J. Bonda et al. Neuroscience Bulletin
- β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer’s disease
- (2014) Kelly Willemijn Menting et al. Frontiers in Aging Neuroscience
- CSF biomarker variability in the Alzheimer's Association quality control program
- (2013) Niklas Mattsson et al. Alzheimers & Dementia
- Designing drug trials for Alzheimer’s disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force
- (2013) Bruno Vellas et al. Alzheimers & Dementia
- 2013 Alzheimer's disease facts and figures
- (2013) Alzheimers & Dementia
- The future of blood-based biomarkers for Alzheimer's disease
- (2013) Kim Henriksen et al. Alzheimers & Dementia
- Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020
- (2013) Harald Hampel et al. BIOCHEMICAL PHARMACOLOGY
- Brain amyloid-β oligomers in ageing and Alzheimer’s disease
- (2013) Sylvain E. Lesné et al. BRAIN
- Inflammatory components in human Alzheimer’s disease and after active amyloid-β42 immunization
- (2013) Elina Zotova et al. BRAIN
- Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease
- (2013) Aaron H. Burstein et al. CLINICAL NEUROPHARMACOLOGY
- Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease
- (2013) Jaren W. Landen et al. CLINICAL NEUROPHARMACOLOGY
- Lymphocyte mitochondria: toward identification of peripheral biomarkers in the progression of Alzheimer disease
- (2013) Rukhsana Sultana et al. FREE RADICAL BIOLOGY AND MEDICINE
- Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimerâs disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study
- (2013) Izuru Miyoshi et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches
- (2013) J. A. Mikulca et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Fluid biomarkers in Alzheimer’s disease – current concepts
- (2013) Christoffer Rosén et al. Molecular Neurodegeneration
- Biomarker Modeling of Alzheimer’s Disease
- (2013) Clifford R. Jack et al. NEURON
- Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer’s Disease
- (2013) Kaj Blennow et al. NEUROPSYCHOPHARMACOLOGY
- A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
- (2013) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neuroimaging and the Search for a Cure for Alzheimer Disease
- (2013) Jeffrey R. Petrella RADIOLOGY
- Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
- (2013) Jon B Toledo et al. Alzheimers Research & Therapy
- Plasma tau levels in Alzheimer's disease
- (2013) Henrik Zetterberg et al. Alzheimers Research & Therapy
- Neurotoxicity of Amyloid -Protein: Synaptic and Network Dysfunction
- (2013) L. Mucke et al. Cold Spring Harbor Perspectives in Medicine
- Hyperphosphorylation-Induced Tau Oligomers
- (2013) Khalid Iqbal et al. Frontiers in Neurology
- Evaluation of Plasma Proteomic Data for Alzheimer Disease State Classification and for the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease
- (2012) Daniel A. Llano et al. ALZHEIMER DISEASE & ASSOCIATED DISORDERS
- Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease
- (2012) Martin Farlow et al. Alzheimers & Dementia
- Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints
- (2012) Argonde C. van Harten et al. Alzheimers & Dementia
- Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls
- (2012) Thomas J. Esparza et al. ANNALS OF NEUROLOGY
- Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia
- (2012) Peder Buchhave ARCHIVES OF GENERAL PSYCHIATRY
- Plasma Amyloid-β as a Predictor of Dementia and Cognitive Decline
- (2012) Alain Koyama et al. ARCHIVES OF NEUROLOGY
- Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease
- (2012) James D. Doecke ARCHIVES OF NEUROLOGY
- Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease
- (2012) Henrik Zetterberg ARCHIVES OF NEUROLOGY
- Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease
- (2012) Vladimir Coric et al. ARCHIVES OF NEUROLOGY
- Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer’s disease
- (2012) Anne M Fagan et al. Biomarkers in Medicine
- Effects of Single Doses of Avagacestat (BMS-708163) on Cerebrospinal Fluid Aβ Levels in Healthy Young Men
- (2012) Gary Tong et al. CLINICAL DRUG INVESTIGATION
- Use of proteomic methods in the analysis of human body fluids in Alzheimer research
- (2012) Petra Zürbig et al. ELECTROPHORESIS
- The mechanism of γ-Secretase dysfunction in familial Alzheimer disease
- (2012) Lucía Chávez-Gutiérrez et al. EMBO JOURNAL
- Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010
- (2012) Thomas G. Beach et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Differential Effects between -Secretase Inhibitors and Modulators on Cognitive Function in Amyloid Precursor Protein-Transgenic and Nontransgenic Mice
- (2012) Y. Mitani et al. JOURNAL OF NEUROSCIENCE
- An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A Binding Properties Promotes Neuroprotection and Glial Engulfment of A
- (2012) O. Adolfsson et al. JOURNAL OF NEUROSCIENCE
- Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis
- (2012) Reisa Sperling et al. LANCET NEUROLOGY
- Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
- (2012) Bengt Winblad et al. LANCET NEUROLOGY
- Gene mutation defends against Alzheimer’s disease
- (2012) Ewen Callaway NATURE
- A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
- (2012) Thorlakur Jonsson et al. NATURE
- CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease
- (2012) R. Tarawneh et al. NEUROLOGY
- Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease
- (2012) W. T. Hu et al. NEUROLOGY
- A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
- (2012) Ronald B. DeMattos et al. NEURON
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
- (2012) Randall J. Bateman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: Results of a pilot study
- (2012) Jeffrey Randall et al. RESUSCITATION
- Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid
- (2011) Stephen D. Weigand et al. Alzheimers & Dementia
- Biomarkers in Alzheimer's disease drug development
- (2011) Jeffrey L. Cummings Alzheimers & Dementia
- Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Reisa A. Sperling et al. Alzheimers & Dementia
- The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Guy M. McKhann et al. Alzheimers & Dementia
- The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Marilyn S. Albert et al. Alzheimers & Dementia
- Visinin-like protein-1: Diagnostic and prognostic biomarker in Alzheimer disease
- (2011) Rawan Tarawneh et al. ANNALS OF NEUROLOGY
- Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)
- (2011) Paul S. Aisen et al. Archives of Medical Science
- DETERMINATION OF SERUM VISININ LIKE PROTEIN-1 AND ITS POTENTIAL FOR THE DIAGNOSIS OF BRAIN INJURY DUE TO THE STROKE - A PILOT STUDY
- (2011) David Stejskal et al. BIOMEDICAL PAPERS-OLOMOUC
- Tau and p-tau as CSF biomarkers in dementia: a meta-analysis
- (2011) Argonde C. van Harten et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Incidence of Post-Dural Puncture Headache in Research Volunteers
- (2011) Sérgio Monteiro de Almeida et al. HEADACHE
- γ-Secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment
- (2011) Ting Li et al. JOURNAL OF NEUROCHEMISTRY
- Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jakob disease
- (2011) Moeko Noguchi-Shinohara et al. JOURNAL OF NEUROLOGY
- Amyloid-β forms fibrils by nucleated conformational conversion of oligomers
- (2011) Jiyong Lee et al. Nature Chemical Biology
- The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
- (2011) Eric Karran et al. NATURE REVIEWS DRUG DISCOVERY
- CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease
- (2011) R. Perneczky et al. NEUROLOGY
- Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease
- (2011) Richard J. Perrin et al. PLoS One
- A Blood-Based Screening Tool for Alzheimer's Disease That Spans Serum and Plasma: Findings from TARC and ADNI
- (2011) Sid E. O'Bryant et al. PLoS One
- YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
- (2010) Rebecca Craig-Schapiro et al. BIOLOGICAL PSYCHIATRY
- Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study
- (2010) Felix Bermejo-Pareja et al. BMC Neurology
- Beneficial effect of human anti-amyloid-β active immunization on neurite morphology and tau pathology
- (2010) Alberto Serrano-Pozo et al. BRAIN
- Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease
- (2010) Annika Thorsell et al. BRAIN RESEARCH
- High-molecular-weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients
- (2010) Hiroaki Fukumoto et al. FASEB JOURNAL
- 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
- (2010) Juha O Rinne et al. LANCET NEUROLOGY
- Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
- (2010) Kaj Blennow et al. Nature Reviews Neurology
- Neuroinflammation – An Early Event in Both the History and Pathogenesis of Alzheimer’s Disease
- (2010) Piet Eikelenboom et al. Neurodegenerative Diseases
- Alzheimer's disease and infection: Do infectious agents contribute to progression of Alzheimer's disease?
- (2009) Kie Honjo et al. Alzheimers & Dementia
- Amyloid precursor protein transgenic mouse models and Alzheimer's disease: Understanding the paradigms, limitations, and contributions
- (2009) Tyler A. Kokjohn et al. Alzheimers & Dementia
- A γ-secretase inhibitor decreases amyloid-β production in the central nervous system
- (2009) Randall J. Bateman et al. ANNALS OF NEUROLOGY
- Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
- (2009) Tero Tapiola et al. ARCHIVES OF NEUROLOGY
- Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders
- (2009) Bruno Vellas et al. Current Alzheimer Research
- Cerebrospinal fluid tau and ptau181increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease
- (2009) Anne M. Fagan et al. EMBO Molecular Medicine
- Amyloid β and APP as biomarkers for Alzheimer’s disease
- (2009) Henrik Zetterberg et al. EXPERIMENTAL GERONTOLOGY
- CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
- (2009) Niklas Mattsson JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Relationship of Cerebrospinal Fluid Markers to 11C-PiB and 18F-FDDNP Binding
- (2009) N. Tolboom et al. JOURNAL OF NUCLEAR MEDICINE
- How can we recognize “disease modification” effects?
- (2009) E. R. Siemers Journal of Nutrition Health & Aging
- Begacestat (GSI-953): A Novel, Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein -Secretase for the Treatment of Alzheimer's Disease
- (2009) R. L. Martone et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- τ Proteins in Serum Predict Outcome After Severe Traumatic Brain Injury
- (2009) Po-Chou Liliang et al. JOURNAL OF SURGICAL RESEARCH
- Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575
- (2009) Monica Garcia-Alloza et al. Molecular Neurodegeneration
- Transmission and spreading of tauopathy in transgenic mouse brain
- (2009) Florence Clavaguera et al. NATURE CELL BIOLOGY
- Oligomerization Partially Explains the Lowering of Aβ42 in Alzheimer’s Disease Cerebrospinal Fluid
- (2009) Hillevi Englund et al. Neurodegenerative Diseases
- MRI and CSF biomarkers in normal, MCI, and AD subjects: Diagnostic discrimination and cognitive correlations
- (2009) P. Vemuri et al. NEUROLOGY
- A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
- (2009) S. Salloway et al. NEUROLOGY
- Age, Neuropathology, and Dementia
- (2009) George M. Savva et al. NEW ENGLAND JOURNAL OF MEDICINE
- Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease
- (2009) Peder Buchhave et al. PLoS One
- Amyloid Goes Global
- (2009) I. Bezprozvanny Science Signaling
- Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease
- (2008) Alex E. Roher et al. Alzheimers & Dementia
- YKL-40, a Marker of Simian Immunodeficiency Virus Encephalitis, Modulates the Biological Activity of Basic Fibroblast Growth Factor
- (2008) Dafna Bonneh-Barkay et al. AMERICAN JOURNAL OF PATHOLOGY
- Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease
- (2008) Adam S. Fleisher et al. ARCHIVES OF NEUROLOGY
- Elevated Cerebrospinal Fluid BACE1 Activity in Incipient Alzheimer Disease
- (2008) Henrik Zetterberg et al. ARCHIVES OF NEUROLOGY
- Plasma β Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men
- (2008) Johan Sundelöf et al. ARCHIVES OF NEUROLOGY
- Immunotherapy Reduces Vascular Amyloid- in PDAPP Mice
- (2008) S. Schroeter et al. JOURNAL OF NEUROSCIENCE
- Dynamics of A Turnover and Deposition in Different -Amyloid Precursor Protein Transgenic Mouse Models Following -Secretase Inhibition
- (2008) D. Abramowski et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
- (2008) Clive Holmes et al. LANCET
- Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study
- (2008) P Lewczuk et al. MOLECULAR PSYCHIATRY
- Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests
- (2008) K A Bates et al. MOLECULAR PSYCHIATRY
- Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of β-secretase
- (2008) Mohammad Ali Faghihi et al. NATURE MEDICINE
- Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment
- (2008) Oskar Hansson et al. NEUROBIOLOGY OF AGING
- Antibody Capture of Soluble Aβ Does Not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse
- (2008) Peter Seubert et al. Neurodegenerative Diseases
- Progress in the Active Immunotherapeutic Approach to Alzheimer’s Disease: Clinical Investigations into AN1792-Associated Meningoencephalitis
- (2008) Michael Pride et al. Neurodegenerative Diseases
- Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study
- (2008) O. L. Lopez et al. NEUROLOGY
- Measuring target effect of proposed disease-modifying therapies in Alzheimer’s disease
- (2008) Randall J. Bateman et al. Neurotherapeutics
- Peripheral A subspecies as risk biomarkers of Alzheimer's disease
- (2008) N. Schupf et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Developing a simple laboratory test for Alzheimer's disease: measuring acetylcholinesterase in saliva - a pilot study
- (2007) Paul F Boston et al. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
- Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia
- (2007) Sebastiaan Engelborghs et al. NEUROBIOLOGY OF AGING
- Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment
- (2007) Miroslaw Brys et al. NEUROBIOLOGY OF AGING
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started